Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

NCT02628067 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT02628067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 18, 2015
Completion date
May 4, 2027
Enrollment
1,609 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumors, anal cancer, anal carcinoma, bile duct cancer, biliary cancer, carcinoid tumor, cervical cancer, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, endometrial cancer, endometrial carcinoma, mesothelioma, neuroendocrine tumor, parotid gland cancer, salivary cancer, salivary gland cancer, salivary gland carcinoma, small cell lung cancer (sclc), small cell lung carcinoma, thyroid cancer, thyroid carcinoma, vulvar cancer, vulvar carcinoma